Want to see EVMN full AI Analyst Report?
EVMN Stock Chart & Stats
$14.65
-$0.09(-0.63%)
At close: 4:00 PM EDT
$14.65
-$0.09(-0.63%)
Day’s Range― - ―
52-Week Range$10.47 - $33.20
Previous Close$14.12
Volume694.64K
Average Volume (3M)935.27K
Market Cap
$531.68M
Enterprise Value$288.08
Total Cash (Recent Filing)$200.79M
Total Debt (Recent Filing)$8.11M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Dec 10, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding36,292,114
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.00Price Target Upside84.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.01
Revenue Forecast (FY)$6.63M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth over 2023-2025 indicates improving commercial traction or milestone-driven revenue. Durable revenue expansion can reduce future financing needs, support reinvestment in R&D, and improve operating leverage as programs scale, benefiting long-term viability.
Balance Sheet StrengthA material recapitalization dramatically reduced leverage and produced positive equity, lowering insolvency and refinancing risk. This stronger capital structure gives management flexibility to fund clinical programs and partnerships over the medium term, provided cash burn is controlled.
Advancing Pipeline (Migraine Phase 2b)Initiation of a global Phase 2b for EVO756 reflects program maturation and resource allocation to a high-unmet-need indication. A successful readout could create a differentiated oral treatment franchise, diversify revenue sources, and materially strengthen long-term commercial prospects.
Bears Say
Worsening Cash BurnRapidly increasing operating and free cash outflows indicate the company is consuming capital faster as programs advance. Persistent worsening cash burn raises the probability of future financings, dilution, or program prioritization decisions that could slow development or commercial launches.
Persistent Net LossesLarge, sustained net losses show the cost base significantly exceeds current revenue, implying profitability is distant. This structural loss profile pressures margins and requires continued external capital or substantial revenue acceleration to avoid undermining long-term independence.
Clinical Setback RiskA failed Phase 2b and halted indication reduces addressable market and highlights clinical risk for EVO756. Program attrition raises the bar for remaining indications to deliver value, may delay commercialization timelines, and increases dependency on fewer successful trials to justify investment.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $10.47 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $531.68M.
When is Evommune, Inc.’s upcoming earnings report date?
Evommune, Inc.’s upcoming earnings report date is Dec 10, 2026 which is in 115 days.
How were Evommune, Inc.’s earnings last quarter?
Evommune, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.664 by -$0.226.
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate is -0.83.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,292,114 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Evommune, Inc. reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.664. Following the earnings report the stock price went up 5.232%.
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.00 (84.30% Upside)
$27.00 (84.30% Upside)
Blogger Sentiment
Bullish
EVMN Sentiment 100%
Sector Average 59%
Sector Average 59%
Hedge Fund Trend
Decreased
By 448.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $146.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
213.84%
Trailing 12-Months
Company Description
Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$27.00
▲(84.30% Upside)
Ownership Overview
52.09% Insiders
11.50% Mutual Funds
29.89% Other Institutional Investors
1.47% Public Companies and
Individual Investors